Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment

Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs

(2022) Feng Wei et al.   TOXICOLOGICAL SCIENCES

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy

(2020) Kendall B. Wallace et al.   CIRCULATION RESEARCH

The long and winding road of cardiomyocyte maturation

(2020) Giovanni Maroli et al.   CARDIOVASCULAR RESEARCH

Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

(2020) Hugo M. Vargas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)

(2020) David G. Strauss et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell

(2019) Nazish Sayed et al.   CARDIOVASCULAR RESEARCH

Clinical trial in a dish: personalized stem cell derived cardiomyocyte assay compared to clinical trial results for two QT prolonging drugs

(2019) Ksenia Blinova et al.   CTS-Clinical and Translational Science

Unlocking Personalized Biomedicine and Drug Discovery with Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Fit for Purpose or Forever Elusive?

(2019) Tessa de Korte et al.   Annual Review of Pharmacology and Toxicology

Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association

(2019) Gary Gintant et al.   CIRCULATION RESEARCH

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms

(2019) Brian D. Guth et al.   Frontiers in Pharmacology

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes

(2019) Alexandre J. S. Ribeiro et al.   Frontiers in Pharmacology

Workshop Report

(2019) Li Pang et al.   CIRCULATION RESEARCH

Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay

(2019) Andre Monteiro da Rocha et al.   TOXICOLOGICAL SCIENCES

Comprehensive review of cardiovascular toxicity of drugs and related agents

(2018) Přemysl Mladěnka et al.   MEDICINAL RESEARCH REVIEWS

A human population-based organotypic in vitro model for cardiotoxicity screening

(2018) Fabian Grimm   ALTEX-Alternatives to Animal Experimentation

CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion

(2018) Rob Wallis et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

(2018) Ksenia Blinova et al.   Cell Reports

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

(2018) David G. Strauss et al.   Therapeutic Innovation & Regulatory Science

In Vitro Metabolite Formation in Human Hepatocytes and Cardiomyocytes and Metabolism and Tissue Distribution in Monkeys of the 2′-C-Methylguanosine Prodrug BMS-986094

(2017) Wenying Li et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling

(2017) Leonardo Schirone et al.   Oxidative Medicine and Cellular Longevity

Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform

(2016) Chris Denning et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Drugs That May Cause or Exacerbate Heart Failure

(2016) Robert L. Page et al.   CIRCULATION

Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys

(2016) Christopher P. Regan et al.   HEPATOLOGY

Identification of Drug–Drug InteractionsIn Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes

(2016) Daniel C. Millard et al.   TOXICOLOGICAL SCIENCES

Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function

(2016) Bethany R. Baumgart et al.   TOXICOLOGICAL SCIENCES

From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor

(2016) Michael Gill et al.   TOXICOLOGICAL SCIENCES

Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav 1.2 over-expressing cells

(2016) Armando Lagrutta et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys

(2015) S Luo et al.   HUMAN & EXPERIMENTAL TOXICOLOGY

Engineering Adolescence

(2014) Xiulan Yang et al.   CIRCULATION RESEARCH

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

(2013) Philip T. Sager et al.   AMERICAN HEART JOURNAL

Induced Pluripotent Stem Cell–Derived Cardiomyocytes

(2013) Björn C. Knollmann   CIRCULATION RESEARCH

The pathophysiology of heart failure

(2012) Clinton D. Kemp et al.   CARDIOVASCULAR PATHOLOGY